DrugPatentWatch Database Preview

Details for Patent: 8,188,104

« Back to Dashboard

Which drugs does patent 8,188,104 protect, and when does it expire?

Patent 8,188,104 protects VIEKIRA XR and VIEKIRA PAK (COPACKAGED) and is included in two NDAs.

This patent has forty-four patent family members in twenty-one countries.

Summary for Patent: 8,188,104

Title:	Anti-infective agents and uses thereof
Abstract:	This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Inventor(s):	Flengte; Charles A. (Salem, WI), Hutchinson; Douglas K. (Antioch, IL), Betebenner; David A. (Libertyville, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Kati; Warren M. (Gurnee, IL), Krueger; Allan C. (Gurnee, IL), Liu; Dachun (Waukegan, IL), Liu; Yaya (Buffalo Grove, IL), Longenecker; Kenton L. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Motter; Christopher E. (Oak Creek, WI), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Stewart; Kent D. (Gurnee, IL), Wagner; Rolf (Antioch, IL), Chen; Shuang (Gurnee, IL), Gao; Yi (Vernon Hills, IL), Lou; Xiaochun (Long Grove, IL), Zhang; Geoff G. Z. (Libertyville, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	12/212,323
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,188,104
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 8,188,104

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y	Y		USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Abbvie Inc	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir	TABLET, TABLET;ORAL	206619-001	Dec 19, 2014		RX	Yes	Yes			Y	Y		USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

International Family Members for US Patent 8,188,104

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	519746
Canada	2699986
Canada	2849420
China	101842360
China	102746240
China	104628654